Clinical significance of systemic inflammation response index and platelet–lymphocyte ratio in patients with stage I-III gastric cancer

Figure 1 Flow diagram of the study design. DCA: Decision curve analysis; ROC: Receiver operating characteristic.

Figure 2 Kaplan-Meier analysis of overall survival in patients with stage I-III gastric cancer who were divided into three groups according to systemic inflammation response index-platelet-to-lymphocyte ratio in the training cohort. SIRI-PLR: Systemic inflammation response index-platelet-to-lymphocyte ratio.

Figure 3 Construct a nomogram for predicting the postoperative overall survival of patients with stage I-III gastric cancer. SIRI-PLR: Systemic inflammation response index-platelet-to-lymphocyte ratio; CEA: Carcinoembryonic antigen.

Figure 4 Receiver operating characteristic curve. A: Receiver operating characteristic (ROC) curve of Nomogram model predicting 1-year, 2-year, and 3-year prognosis of patients in the training set; B: ROC curve of Nomogram model predicting 1-year, 2-year, and 3-year prognosis of patients in the validation set; C: C-index of the training group; D: C-index of the validation group; E: The decision analysis curve of the training group; F: The decision analysis curve of the validation group; G: Calibration curves for predicting 1-year, 2-year, and 3-year overall survival (OS) rates of patients with stage I-III gastric cancer (GC) in the training cohort. The actual OS rates are plotted on the Y-axis, while the OS rates predicted by the nomogram are plotted on the X-axis; H: Calibration curves for predicting the 1-year, 2-year, and 3-year OS rates of patients with stage I-III GC in the validation cohort. AUC: Area under the receiver operating characteristic curve.